Experimental approaches to studies on drug metabolism and drug interactions in man: Interaction of acyclic nucleoside phosphonates with human liver cytochromes P450 and flavin-containing monooxygenase 3

Neuroendocrinology Letters

Volumn 27, Issue SUPPL. 2, 2006, Pages 27-30

  Matal, Jaroslav ^a   Orság, Jiří ^a   Nekvindová, Jana ^a   Anzenbacherová, Eva ^a   Veinlichová, Alena ^a   Anzenbacher, Pavel ^a   Zídek, Zdeněk ^b   Holý, Antonín ^c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Adefovir; CYP; Cytochromes P450; Drug interactions; Flavin containing monoxygenase 3; FMO3; Liver microsomes; Tenofovir

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 3; LIVER ENZYME; PHOSPHONIC ACID DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ARTIFICIAL MEMBRANE; BACTERIAL MEMBRANE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RECONSTITUTION; HUMAN; IN VITRO STUDY; LIVER MICROSOME METABOLISM; NONHUMAN;

EID: 34047231012     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF eds. Drug Interactions Handbook. 2nd ed. Hudson (OH): Lexi-Comp. 2004.
2. Cashman JR. Human Flavin-Containing Monooxygenase: Substrate specificity and role in drug metabolism. Curr Drug Metab. 2000; 1:181-91.
3. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR ed. Cytochrome P450, structure, mechanism and biochemistry. New York: Kluwer Academic/Plenum; 2005: p.377-530.
4. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate, clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612.
5. Kotrbová V, Aimová D, Březinová A, Janouchová K, Poljaková J, Hodek P. et al. Cytochromes P450 Reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuroendocrinol Lett. 2006; 27 (Suppl.2): 18-22.
6. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphism and role in drug metabolism. Pharmacology & Therapeutics. 2005; 106(3):357-87.
7. Nekvindová J, Mašek V, Veinlichová A, Anzenbacherová E, Anzenbacher P, Zídek Z. et al. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica. 2006; in press
8. Parkinson A Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett and Doull's toxicology. 6th ed. New York: McGraw-Hill; 2001. p.133-204.
9. Phillips IR, Shephard EA, editors. Cytochrome P450 protocols. Totowa (NJ): Humana Press. 1998.
10. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001; 41(11):1149-79.
11. Zuber R, Anzenbacherová E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Medicine. 2002; 6(2):189-98.